Understanding how TSG-6 protein contributes to the natural protection of joint tissues against osteoarthritis.
Disease - Osteoarthritis
Lead applicant - Professor Anthony Day
Organisation - University of Manchester
Type of grant - Full Application Disease
Status of grant - Active
Amount of the original award - £1,226,186.00
Start date - 1 January 2020
Reference - 22277
What are the aims of this research?
This research aims to establish how a protein called TSG-6 (which is only produced in human tissues during inflammation) contributes to the natural protection of joint tissues in osteoarthritis. By understanding the mechanism of TSG-6 production, the researchers hope to progress the development of a new drug, called Link_TSG6.
Why is this research important?
Previous research has indicated that the TSG-6 protein may be a natural protector of cartilage and other joint tissues. Researchers are in the early stages of developing a ‘biological’ drug based on this protein, called Link_TSG6, that has the potential to reduce both cartilage damage and pain. The researchers will use cell-imaging and gene-editing techniques to measure TSG-6 production in osteoarthritis patients, from disease onset through to established osteoarthritis. It is hoped that this knowledge will progress the development of this drug and gain the support of the pharmaceutical industry.
How will the findings benefit patients?
There are still no drugs to prevent progression of osteoarthritis, and more than 160,000 joint replacements are performed each year in the UK to relieve pain and restore function. People with osteoarthritis have identified a major need for treatments to reduce symptoms and delay the need for surgery. The knowledge from this study could underpin the development of a new class of drugs as well as enabling personalised medicine approaches that tailor treatment to patients’ individual needs.